Category: Digest

Towards a Better Definition of Therapeutic Concepts in Atopic Dermatitis: Learning from Rheumatoid Arthritis Dear Colleagues, Dear Friends, Since the 1980s, rheumatoid arthritis (RA) has served as a model for therapeutic strategies in chronic inflammatory diseases. RA activity is assessed using multiple measures, including swollen joint counts, inflammatory markers, and radiographic signs of joint damage. […]

AI in AD and Allergy Research: Enhancing Collaboration with AI Experts Dear Colleagues, Dear Friends, Advances in AI over the past two years have significantly transformed the medical landscape, challenging vigorously our professional environment. A thorough review by Lisik et al. [link] provides an insightful overview of AI’s applications in AD and allergy research—a field […]

Buzzes and controversies of last year in the AD literature Dear Colleagues, Dear Friends, On behalf of ISAD, I extend my best wishes for a bright and successful New Year, filled with new achievements that will benefit our patients. We are actively planning our 2025 meetings and are excited to share some updates. Our Spring […]

AD evidence-based medicine outcome instruments: how to better integrate patients’ preferences? Dear Colleagues, Dear Friends, A recently published study funded by Galderma investigates with the quantitative method named discrete choice experiment (DCE) the preference of patients and physicians when prescribing systemic treatments for AD. This DCE method is increasingly used in healthcare to elicit preferences […]

ISAD plans a celebration of the Centennial birthday anniversary of Georg RAJKA (1925-2013) next year in Melbourne, Australia Dear Colleagues, Dear Friends, Fleeing Hungary, his native country, after the Soviet occupation, Georg RAJKA made in Sweden then Norway an outstanding and very original academic career centered on Prurigo Besnier/AD. Prurigo Besnier was indeed the name […]

Are dermatology professionals needed to balance the influence of TikTok and other social networks? Dear Colleagues, Dear Friends, The hashtag #topicalsteroidwithdrawal (TSW) got more than 600 million views on TikTok. A recent Lebanese study (doi: 10.2196/48389) did a great job by studying the content of this hashtag and by trying to alert our community on […]

Which research priorities for AD in 2024? Curative precision medicine vs preventive exposome-targeted medicine. Dear Colleagues, Dear Friends, In a recently published provocative perspective paper (DOI: 10.3389/fpubh.2024.1351732), Ian A. Myles, a NIH researcher, asks some good questions to our community which could help shaping our priorities. Currently, with the industry-led dramatic development of biologics and […]

#RAJKA2024Doha #RAJKAMedal Dear Colleagues, Dear Friends, The abstract submission to the 14th Georg Rajka Symposium on AD (Doha, Qatar, October 24-26, 2024) closed as scheduled on July 15th. 149 abstracts from 32 countries were received. They are currently adjudicated, and the outcome will be available soon in second half of August. All accepted abstracts will be […]

What PubMed tell us about current trends in AD research? Dear Colleagues, Dear Friends, Since the approval of dupilumab for severe adult AD by the FDA in 2017, published AD research has been tremendously driven by RCTs and associated research concerning dupilumab and other new systemic/ topical therapies designed to control TH2 inflammation. The influence […]

The 2024 Rajka Medal and Prize will be attributed, please have a look at the criteria to apply, this year will be very competitive! From 2024, an accompanying prize of 15.000 EUR will be given to the awardee to contribute to further research at his/her institution. In memory of Professor Georg RAJKA and his pioneering […]